P1038 TL-895, A first-in-class, covalent bruton tyrosine kinase inhibitor (BTKI) for the treatment of myelofibrosis (MF) patients (PTS) with severe thrombocytopenia (platelets (PLTS)<50 K/UL)

Loschi, MichaelRejtő, LászlóChuah, HunCaramella, MariannaHernández Rivas, JesusSportoletti, PaoloDubruille, VivianeBellesso, MarceloGröpper, StefanieCrodel, CarlQamoos, HopeSocotch, AshleyHuang, ZhuyingWall, SarahMcGreivy, Jesse S.Rothbaum, WayneVerstovsek, SrdanPalandri, Francesca2023-09-112023-09-112023HemaSphere. -7 : Suppl_3 (2023), p. 1983-1985. -(cikkazonosító)e09624cd. -Hemasphere. - 2572-92412572-9241https://hdl.handle.net/2437/358843P1038 TL-895, A first-in-class, covalent bruton tyrosine kinase inhibitor (BTKI) for the treatment of myelofibrosis (MF) patients (PTS) with severe thrombocytopenia (platelets (PLTS)<50 K/UL)folyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM114551OrvostudományokKlinikai orvostudományokhttps://journals.lww.com/10.1097/01.HS9.0000971048.09624.cdhttp://dx.doi.org/10.1097/01.HS9.0000971048.09624.cd2023-09-11